COVID-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Treatment-Focused Review.
| Autor: | Waleed MS; Internal Medicine, Lower Bucks Hospital, Bristol, USA., Dhulipalla L; Hematology and Oncology, Northwell Health, Staten Island, USA., Niazi M; Internal Medicine, Northwell Health/Staten Island University Hospital, Staten Island, USA., Terjanian T; Hematology and Oncology, Staten Island University Hospital, Staten Island, USA., Dhar M; Hematology and Oncology, Staten Island University Hospital, Staten Island, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Mar 30; Vol. 16 (3), pp. e57252. Date of Electronic Publication: 2024 Mar 30 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.57252 |
| Abstrakt: | Thrombotic thrombocytopenic purpura (TTP) is a rare disease that is part of a vast spectrum of thrombotic microangiopathies (TMAs). Despite the rarity of TTP, clinicians must maintain a high suspicion of this disease. The condition is characterized by fever, low platelets, hemolytic anemia, renal abnormalities, and neurological dysfunction. However, all these symptoms are not necessarily present in all the patients. In this review, we describe a case of a 51-year-old female who presented to the emergency department (ED) with chief complaints of dizziness and lightheadedness, subsequently leading to a diagnosis of TTP, caused as a result of COVID-19. This review raises awareness so that there is early recognition of any hematological manifestations associated with COVID-19, reducing the morbidity and mortality associated with the disease. Due to the unpredictability of COVID-19 and its complications, robust research is needed to understand the mechanism and determine which patients are more at risk for adverse outcomes. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Waleed et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|